These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2108832)

  • 1. Kawasaki disease and oxidative metabolism.
    Lebranchu Y; Malvy D; Richard MJ; Arnaud J; Favier A; Bardos P
    Clin Chim Acta; 1990 Mar; 187(3):193-8. PubMed ID: 2108832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antioxidant enzymes and lipoperoxide in blood in patients with Kawasaki disease. Comparison with the changes in acute infections.
    Uchida N; Asayama K; Dobashi K; Hayashibe H; Kato K
    Acta Paediatr Jpn; 1990 Jun; 32(3):242-8. PubMed ID: 2239296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased circulating granulocyte colony-stimulating factor in acute Kawasaki disease.
    Inoue Y; Kato M; Kobayashi T; Shinohara M; Sone K; Morikawa A
    Pediatr Int; 1999 Jun; 41(3):330-3. PubMed ID: 10365591
    [No Abstract]   [Full Text] [Related]  

  • 4. Spontaneous tumor necrosis factor production in Kawasaki disease.
    Lang BA; Silverman ED; Laxer RM; Lau AS
    J Pediatr; 1989 Dec; 115(6):939-43. PubMed ID: 2585231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease.
    Cabana VG; Gidding SS; Getz GS; Chapman J; Shulman ST
    Pediatr Res; 1997 Nov; 42(5):651-5. PubMed ID: 9357939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased plasma lipid peroxidation in riboflavin-deficient, malaria-infected children.
    Das BS; Thurnham DI; Patnaik JK; Das DB; Satpathy R; Bose TK
    Am J Clin Nutr; 1990 May; 51(5):859-63. PubMed ID: 2185624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for increased oxidative damage in patients with cystic fibrosis.
    Brown RK; Kelly FJ
    Pediatr Res; 1994 Oct; 36(4):487-93. PubMed ID: 7816524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kawasaki disease. Treatment with intravenous gammaglobulins].
    Lebranchu Y
    Presse Med; 1989 Jun; 18(23):1147-50. PubMed ID: 2472630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children.
    Okada Y; Shinohara M; Kobayashi T; Inoue Y; Tomomasa T; Kobayashi T; Morikawa A;
    J Pediatr; 2003 Sep; 143(3):363-7. PubMed ID: 14517521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered lipid profile after Kawasaki syndrome.
    Newburger JW; Burns JC; Beiser AS; Loscalzo J
    Circulation; 1991 Aug; 84(2):625-31. PubMed ID: 1860206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between hydroperoxides and malondialdehyde as markers of acute oxidative injury during hemodialysis.
    Lucchi L; Iannone A; Bergamini S; Stipo L; Perrone S; Uggeri S; Gatti V; Ferrari F; Tomasi A; Albertazzi A
    Artif Organs; 2005 Oct; 29(10):832-7. PubMed ID: 16185346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of plasma exchange therapy for Kawasaki disease by cytokine profiling.
    Kashiwagi Y; Kawashima H; Akamatsu N; Morishima Y; Nishimata S
    Ther Apher Dial; 2012 Jun; 16(3):281-3. PubMed ID: 22607573
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential protein analysis of serum exosomes post-intravenous immunoglobulin therapy in patients with Kawasaki disease.
    Zhang L; Song QF; Jin JJ; Huang P; Wang ZP; Xie XF; Gu XQ; Gao XJ; Jia HL
    Cardiol Young; 2017 Nov; 27(9):1786-1796. PubMed ID: 28803590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of rapid assay of serum interleukin-6 in Kawasaki disease.
    Suganami Y; Kawashima H; Hasegawa D; Sato S; Hoshika A
    Pediatr Int; 2008 Apr; 50(2):264-6. PubMed ID: 18353077
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme release and O2 production of neutrophils and vascular lesions in gamma globulin therapy of Kawasaki disease.
    Okazaki T; Sakatani T; Sasagawa S; Ohta H; Ohnishi H; Suzuki K
    Prog Clin Biol Res; 1987; 250():557-8. PubMed ID: 3423073
    [No Abstract]   [Full Text] [Related]  

  • 16. CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease.
    Ko TM; Kuo HC; Chang JS; Chen SP; Liu YM; Chen HW; Tsai FJ; Lee YC; Chen CH; Wu JY; Chen YT
    Circ Res; 2015 Feb; 116(5):876-83. PubMed ID: 25605650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor in acute Kawasaki disease.
    Terai M; Yasukawa K; Narumoto S; Tateno S; Oana S; Kohno Y
    Am J Cardiol; 1999 Feb; 83(3):337-9. PubMed ID: 10072219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Circulating interleukin-4 levels in acute phase Kawasaki disease].
    Hirao J; Hibi S; Andoh T; Ichimura T
    Arerugi; 1996 Oct; 45(10):1137-9. PubMed ID: 8958662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels.
    Falcini F; Cerinic MM; Ermini M; Generini S; Lombardi A; Pignone A; Leoncini G; Tirassa P; Aloe L
    J Rheumatol; 1996 Oct; 23(10):1798-802. PubMed ID: 8895162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete Kawasaki disease: a pediatric diagnostic conflict.
    Celik U; Alhan E; Arabaci F
    Anadolu Kardiyol Derg; 2007 Sep; 7(3):343-4. PubMed ID: 17785242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.